Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today ...
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...
Investing.com -- ProPhase Labs Inc (NASDAQ:PRPH) stock surged 75.2% in premarket trading Friday after the company announced a non-binding letter of intent for a reverse merger with Advanced Biological ...
Market Cap: Approximately $12 million. Crown Medical Collections: Estimated to collect at least $50 million net from $150 million in uncollected COVID testing claims. BE-Smart Esophageal Cancer Test: ...
UNIONDALE, NY - ProPhase Labs, Inc. (NASDAQ:PRPH) and European biotechnology group Advanced Biological Laboratories S.A. (ABL) announced Friday they have entered into a non-binding Letter of Intent ...
GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today reported its ...
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the ...
ProPhase Labs is a diversified biotech company with profitable existing product lines and plans for expansion. The company's subsidiary, Nebula Genomics, offers whole genome sequencing and plans to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback